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Abstract
Background
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Capsule endoscopy (CE) is mainstream in the evaluation of obscure
gastrointestinal bleeding (GIB) in the general population. However, the diagnostic
and therapeutic impact of CE in LVAD patients susceptible to transient bleeding
remains largely unexplored. This study aimed to assess the benefits of CE in the
evaluation of LVAD associated GIB.
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Retrospective review of patients implanted with a continuous flow LVAD who
underwent inpatient capsule endoscopy (CE) between January 2014 and May
2017 at our center. Identification of lesions with high bleeding potential or
presence of frank blood were considered abnormal findings on CE study.
Results
Twenty-five inpatients who underwent 41 CE were identified. All patients
presented with GIB and had preceding negative upper endoscopy and
colonoscopy in the past 4 weeks. On the first capsule in each patient, 19 had
interpretable images, abnormal findings were detected in 5 patients (high risk
lesion in 3, frank blood in 2), four of these underwent an enteroscopy and only 2
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(8%) patients had confirmation of the capsule findings with APC treatment (true
positive). Excluding patients with malfunction, LVAD interference and poor bowel
prep, 14 patients had negative/equivocal CE, of which 4 underwent enteroscopy
due to continued bleeding and 2 of these patients had treatable culprit lesions
(false negative). A total of 17 (68%) patients were discharged without any
therapeutic intervention irrespective of the success or findings on CE due to
clinical stabilization. Twenty patients (80%) had recurrence in a mean 154 days.
As expected, repeat capsules in the same admission increased the diagnostic
yield (p=0.031)
Only nine patients (36%) had capsule-image evidence of reaching the cecum while
4 patients (16%) had retention which had to be retrieved without further
complication.
Conclusions
This study demonstrated that evaluation of GIB with CE is feasible and safe but
was associated with a low diagnostic yield and low conversion to therapeutic
intervention. With a true positive yield of 4% in our cohort, the efficacy and costeffectiveness of CE in the LVAD population is debatable. The role of CE in LVAD
patients may need to be reevaluated.
An identification of patients who would benefit from a capsule-first approach would
allow optimum utilization of resources and reduce healthcare expenditure.

Keywords: Gastrointestinal bleeding, capsule endoscopy, left ventricular assist
device, advanced heart failure management

Introduction
Left ventricular assist devices (LVAD) are becoming a progressively more reliable
and safe long term treatment option for advanced heart failure patients. As the
cohort of LVAD patients continues to grow, various complications that are
characteristic of this patient population are becoming evident. Gastrointestinal
bleeding (GIB) has been reported in up to 20% patients and contributes to
significant morbidity including multiple hospitalizations, prolonged in patient stay,
and possibly increased mortality 1,2. While the number of LVAD patients continues
to grow, the ideal approach to further evaluation of GIB without an identified
source on standard evaluation with endoscopy and colonoscopy is unknown.
Based on guidelines, capsule endoscopy (CE) has been adopted as the procedure
of choice in general population for evaluation of gastrointestinal bleeding (GIB)
undiagnosed through upper endoscopy/colonoscopy, especially that estimated to
originate from the small intestine. While these guidelines have been extrapolated
to patients with left ventricular assist device (LVAD), the true efficacy and
therapeutic impact of CE in LVAD patients who are prone to transient but recurrent
bleeding remains largely unexplored. As the diagnostic and treatment strategies
evolve, it is important to understand management options for GIB as well as their
associated limitations. This study aims to assess the necessity of this
comparatively expensive test through understanding the clinical course of patients
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after capsule study and identify its role in screening patients for subsequent
enteroscopy, therapeutic intervention or recurrence prevention.

Methods
Study population:
We performed a retrospective review of patients implanted with a continuous flow
left ventricular assist device (LVAD) who underwent inpatient capsule endoscopy
(CE) between January 2014 and May 2017 at our facility- Jewish Hospital,
Louisville, Kentucky. Appropriate Institutional Review Board exemption was
obtained.
Patients were given either one gallon of GoLytely prep split between the night prior
and morning of the capsule endoscopy study or magnesium citrate prep split with
two 300 mL bottles night prior to and one 300mL bottle the morning of the capsule
endoscopy. Both preps included two tablets of simethicone 80mg the morning of
the capsule endoscopy study.
The PillCam SB2 capsule (Given Imaging, Duluth, GA, United States) was
activated and either swallowed by the patient, or in cases of significant dysphagia
or delayed gastric emptying, was placed through an upper endoscope directly into
the duodenum.
The capsules images were interpreted by certified gastroenterologists. Lesions
identified on video capsule endoscopy were classified using the P0-P2 system as
described previously by Saurin, J.C. et al. in 2003 3. Lesions with no bleeding
potential included P0 lesion such as visible submucosal vasculature, non-specific
nodules and P1 lesions such as erythema, petechiae or insignificant erosions.
Lesions with bleeding potential included P2 lesions such as angiodysplasia, ulcers,
significant erosions or adherent clot. Only studies with P2 lesions or the presence
of frank bleeding without visualized lesions were considered positive.
Subsequent single balloon enteroscopy findings and treatments offered were
noted, confirmation of capsule findings, and treatment with argon plasma
coagulation (APC) or endoclips were considered ‘true positive’ findings. The
available data until June 2017 was reviewed on all the patients including
recurrence and mortality
Statistical analysis:
IBM SPSS (version 19.0, SPSS Corp, Chicago, IL, USA) was used for statistical
analysis. Qualitative data is presented as frequencies and quantitative data as
mean ± standard deviation.

Results
From January 2014 to May 2017, 25 patients had 41 CEs performed. Of the 41
studies, 28 capsules were performed in the same admission, while others had
repeat capsules at 10 days to 7 months for recurrent GIB. Key patient
demographics are shown in Table 1. LVAD type was Heart Ware in 9 patients
(36%), HeartMate II in 14 (56%) and HeartMate III in 2 patients (8%). Presenting
symptoms included melena in 16 patients (64%), hematochezia in 3 (12%), occult
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bleeding in 6 (24%). Twenty one patients (84%) were on aspirin at presentation
(six patients on 81mg, 15 on 325mg). All patients were on warfarin with a mean
INR of 2.54 ± 0.8 on the day of admission.
Table 1: Key demographics
Frequency (%)
Male gender

19 (76%)

Hypertension

22 (88%)

Diabetes

14 (56%)

Ischemic cardiomyopathy

17 (68%)

Destination LVAD therapy

18 (72%)

ICD

23 (92%)

Ongoing infection

8 (32%)

Previous GIB

19 (76%)

ACEinh/ARB use

9 (36%)

Betablocker

18 (72%)

Statin

13 (52%)

PPI

23 (92%)

Capsule was performed 395 ± 467 days after implantation. The capsule
admissions comprised a 10.7 ± 12.4 days inpatient length of stay and the capsule
was performed 3.7 ± 2.1 days after admission. All 25 patients had a preceding
negative upper endoscopy and colonoscopy in the past 4 weeks and 18 patients
(72%) had them on the same hospital admission. Mean transit time for the
capsule was 7.28 ± 1.6 hours. Nine patients (36%) had capsule-image evidence of
reaching the cecum while 4 patients (16%) had capsule retention which had to be
retrieved using upper endoscopy (which occurred without further complication).
While assessing the first capsule endoscopy of each patient, 19 out of 25 patients
completed their first capsule with interpretable images. Of the remaining 6
patients, 2 patients had technical malfunction, 2 had LVAD interference with large
gaps in image acquisition, one had gastric retention, while one had poor bowel
prep. The findings are summarized in figure 1. Of the interpretable 19 CE,
capsule identified the following lesions: P0 lesion in 2 (8%), P1 lesion in 4 (16%)
and P2 lesion in 3 (12%) while blood was seen without any mucosal lesion in 2
(8%) patients. Of the patients with P2 lesion or identified blood, 4 underwent an
enteroscopy and only 2 (8%) patients had findings requiring APC treatment, of
which only 1 (4%) had actual visualization of the capsule lesion and treatment
(true positive) (Table2). Out of the 14 patients with negative/equivocal CE, 4
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underwent endoscopy due to continued bleeding and 2 of these patients had
treatable culprit lesions (false negative) (Table 3).

Figure 1: findings of capsule studies
*Mucosal P2 lesions included patients 3, 4 and 5 in table 2
#
Findings described in table 3
Table 2. Capsules demonstrating abnormal findings
Patient Number

Capsule lesion

Enteroscopy finding Treatment offered

1

Only blood

Oozing from a
previous biopsy site

None

2

Only blood

AVM in jejunum

APC

3

Angioectesia in
proximal small bowel

AVM in jejunum

APC

4

Adherent clot in
duodenum

AVM in jejunum, no
lesion in duodenum

APC

5

Erythematous lesion
versus ulceration in
the gastric body

Not done

None
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Table 3. Endoscopy findings in patients with negative capsules
Patient
Number

Capsule lesion

Endoscopy finding

Treatment offered

6

Negative

Bleeding AVM in
jejunum

APC

7

Negative

Bleeding AVM in
cecum

Endoclip

8

Negative

Negative

None

9

Negative

Negative

None

Thus a total of 8 out of 25 patients (4 with a CE with abnormal findings and 4 with
CE with normal finding) underwent enteroscopy post CE, while 17 (68%) patients
were discharged without any therapeutic intervention irrespective of the finding on
CE because of clinical stabilization Among patients on higher aspirin dose, the
dose was reduced or stopped in 6 (33%) at discharge and this was independent of
the capsule findings.
Ten patients had >1 CE done, 3 patients had them repeated in the same
admission, of these 2 had malfunction of the first capsule while 1 had a negative
first study which prompted a repeat due to continued bleeding. Two of these
repeated capsules had positive findings. As expected, repeating the capsule in the
same admission resulted in better diagnostic yield (p=0.031). The CE which
shortly followed the initial negative study showed blood without a mucosal lesion
and this prompted an enteroscopy and APC of a jejunal lesion and this patient has
not had recurrence since.
Out of the remaining patients with repeat capsules, 2 patients had repeat capsules
delivered through upper endoscopy in subsequent admissions while 2 patients had
3 and 4 CE studies each, all of which were negative. The findings are summarized
in table 4.
Recurrent GIB was seen in 20 (80%) patients in a mean 154 ± 188 days after the
first capsule. Of the 5 patients who had bleeding lesions treated in the initial
admission, 4 had recurrent GIB. Two patients died from non-gastrointestinal
complications (stroke and intracranial bleeding)
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Table 4 Findings of first 2 capsules in patients with repeat capsule
endoscopies
Patient
number

1st Capsule

2nd Capsule

Subsequent
endoscopy findings

1

No Images- LVAD
interference

No images- LVAD
interference

Endoclips applied to
bleeding AVM in
ascending colon

2

Technical malfunction Only blood without
mucosal lesion

Oozing from previous
biopsy site

3

Technical malfunction Only blood without
mucosal lesion

APC of AVM in
jejunum

4

Gastric retention

Negative

Not done

5

Negative

Non-bleeding AVM in
proximal small bowel

Not done

6

Negative

Colonic AVM

APC of bleeding AVM
in cecum

7

Negative

Negative

Not done

8

Negative

Only blood without
mucosal lesion

Not done

9

Negative

Negative

Not done

10

Negative

Negative

Not done

Discussion
The purpose of this study was to evaluate a cohort of LVAD patients undergoing
capsule endoscopy (CE) and assess the impact of this test on the diagnosis,
treatment and long term outcome of LVAD patients. Here, we present a large and
well characterized case series of the use of capsule endoscopies to evaluate
LVAD associated GIB. We found that capsule endoscopy is feasible in LVAD
patients, but is associated with a high rate of inadequate/incomplete studies.
While CE often demonstrate abnormal findings, the clinical utility of the abnormal
findings appears limited.
With the advent of continuous flow LVAD, the incidence of GIB may be expected
to rise4, and risk factors for LVAD associated GIB include older age and renal
dysfunction4. Unlike earlier pulsatile flow LVADs, continuous flow devices require
the use of antiplatelet medications and warfarin. While the use of antiplatelet
agents and anticoagulation may contribute to GIB among LVAD patients, several
https://doi.org/10.13023/VAD.2017.11
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other etiologies for LVAD associated GIB have been identified including acquired
von Willebrand syndrome and impaired platelet aggregation4. Additionally, it has
been proposed that the chronic low pulse pressure caused by continuous flow
devices leads to local tissue hypoperfusion and dilation of vascular beds causing
angiodysplasia formation 5. Clinically significant AVMs may occur as early as 2
months after LVAD implantation and can account for 1/3rd or more of the GIB
cases2,6. Many such patients may have inaccessible locations of the bleeding or
oozing from multiple small and transient vascular ectasias within unreachable
locations of the small intestine. Finding such vague pathological lesions can then
be challenging, requiring multiple diagnostic and therapeutic procedures.
Moreover, the treatment of a culprit-looking lesion does not guarantee against
recurrence in the future, which come more often from new channels of bleeding.
This can be an ongoing issue for some patients resulting in significant frustration,
frequent hospitalization, morbidity and sometimes mortality. In such
circumstances, CE has been adopted as the procedure of choice in evaluation of
GIB when conventional upper and lower endoscopies are unsuccessful in locating
the bleeding within their reachable distances. In cases of GIB without a source
identified on EGD or colonoscopy, visualization of the entire gastrointestinal tract
including the extent of small intestine with CE or enteroscopy has been
recommended7.
After its initial description in 1990s, capsule endoscopy (CE) has become
mainstream in the evaluation of GIB over the past 20 years, especially in patients
with occult bleed8,9. The current guidelines recommend the use of CE as the next
step in evaluation of GIB after conventional upper and lower endoscopies fail to
ascertain the location of the bleed in the general population4. Studies also
recommend CE to precede enteroscopy due to its ability to examine the entire
small intestine in a non-invasive manner4 unless in cases of active bleeding.
Enteroscopy may then be performed in cases with high suspicion for a small
intestinal lesion despite a negative CE10. Using an initial CE approach has been
argued as a means to filter patients who do not need an enteroscopy and thus
may have favorable long term outcomes11.
As the capsule travels through the small intestine, it transmits images to a data
recorder worn by the patient through a radiofrequency channel9. There had been
concerns about interference with implantable devices utilizing radiofrequency
channels such as pacemakers/defibrillators as well as possible electromagnetic
interference with novel technologies such as LVAD9. However, studies have not
shown any such interference12,13. While there are only few published reports so far,
the use of CE in LVAD patients appears safe14,15 however the efficacy and costeffectiveness profile remains largely unexplored.
In a study of CE in 30 LVAD patients15, 12 patients were found to have lesions with
high bleeding potential or frank blood without mucosal lesions on the CE, of which
50% underwent subsequent procedure. However, the findings of these subsequent
procedures and hence confirmation of the exact positive findings (true positive) or
therapeutic interventions performed were not reported in that study. The remaining
6 patients in that cohort with positive CE had stabilization of that clinical course, so
no procedure was pursued. Thus positive finding on CE did not guarantee a
subsequent procedure, a finding similar to our study. In that cohort, the recurrent
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bleeding rate was 50% among patients with positive CE irrespective of therapeutic
interventions performed during the index admission.
There were many differences between the present and the above mentioned study
with similar number of CE. In our study while the 4 enteroscopies performed in
patients with an abnormal CEs did identify abnormalities, only 1 patient (4%) was a
true positive where the CE demonstrated a lesion which was confirmed and
treated on follow-up enteroscopy while another patient had a lesion treated on
enteroscopy after CE demonstrated only blood. It is unclear whether the treated
lesion was the actual source of the visualized blood. The remaining patients with
abnormal findings on CE had non-treatable lesion on enteroscopy (patient # 1 in
table 2) or had subsequent clinical stabilization, so no therapeutic intervention was
offered in that admission despite a seemingly clinically relevant finding (patient #5
in table 2). In fact, out of the 25 patients, 17 patients (68%) were discharged
without any therapeutic intervention subsequent to the CE, irrespective of the
finding of the capsule.
Irrespective of the CE results and subsequent management, the recurrence rate
for subsequent GIB was high (80%) over the course of the study period, with the
first recurrence in a mean of 154 ± 188 days after the first capsule. The low
diagnostic yield of CE in this study, low conversion rates to therapeutic
interventions, high subsequent clinical stabilization rates and the significant
recurrence rate thereafter with absence of direct mortality raises the question of
whether the CE was necessary in these patients. Performing CE in an inpatient
setting may prolong the length of stay and with a true positive yield of 4% in our
cohort of patients, the cost-effectiveness of CE may be debatable.
Amornsawadwattana et al15 in their above mentioned study reported that the
capsule did not reach the cecum in only 2 patients and there was no LVAD
interference with image acquisition with any of the capsules. In the present study
however, imaging evidence of the capsule reaching cecum was available only in 9
patients and capsule retention was noted in 4 patients requiring endoscopic
retrieval which occurred without further complications. Moreover, the yield of CE is
critically based on the quality of the bowel prep, technical and mechanical success
of the capsule, lack of interference and most importantly, the clinical stability of the
patient during the conduct of the study. This significantly restricts the clinical utility
of the test requiring repeated tests. On the other hand, Sarosiek et al16 reported
early enteroscopy approach in LVAD patients resulted in less diagnostic tests and
faster resolution of GIB. However, enteroscopy carries the significant drawback of
being invasive, resource-intensive, physician supervised, requires sedation and
possibly anesthetist backup, along with pain and inconvenience for the patient17.
Also in cases of hidden sources of GIB, CE has been reported to have higher
detection rates than double balloon enteroscopy in general population18 but this
has not been evaluated among LVAD patients.
While the debate for the ideal diagnostic test in obscure GIB rages on in the
literature, it is also important to consider whether the procedure will provide
clinically relevant information in a particular patient. Many such patients may
simply respond to an outpatient ‘wait and watch’ approach based on the treating
physician’s clinical assessment15 unless there is clinical deterioration or
recurrence, in which case a direct enteroscopy approach may be feasible instead.
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The inability to treat the visualized lesions is a significant drawback of CE17,
reducing it to a purely diagnostic or screening procedure.
Also, it is unclear if the higher detection rate with CE translates to higher treatment
rate in LVAD patients as CE is essentially a diagnostic test which will need a
procedure such as enteroscopy to treat the identified lesion. In this study, the
conversion of an abnormal CE finding to a therapeutic enteroscopy was only 2 out
of 5 (40%), which was not notably different from the conversion of a normal CE to
a therapeutic enteroscopy (2 out of 4 patients) in the same hospitalization. Despite
treatment of culprit-looking lesion in 5 patients endoscopically, 4 had recurrent
GIB. While a past history of previous GIB is a predictor of recurrent bleeding, the
majority of recurrence is from the same bleeding site1. Identification of such small,
transient, recurrent culprit-looking lesions on CE may require no further treatment,
however this needs to be further evaluated.
The use of capsule in LVAD patients was a safe procedure in our study, without
any extraneous complications, however capsule retention (4 patients) and LVAD
interference with image acquisition (2 patients) was reported in some patients. It
was suggested that the data recorder be placed far from the LVAD to reduce the
electromagnetic interference9. ICDs are also commonly found in this patient
population which can also be a rare source of interference with image
acquisition19. While these issues do not contraindicate the use of capsules in
LVAD patients, they do suggest judicious use for the highest clinical benefit.
The limitations of the study included the retrospective design and single facility
patient selection. The decision to perform CE or subsequent workup based on the
results of the CE were at the discretion of the GI service. The study was
underpowered for statistical analysis of patients with positive capsules or for
subset analysis of APC treated patients. The site of GIB recurrence was not
evaluated, unless the patient underwent capsule study again.
In summary, this study demonstrates low clinical utility of performing CE in LVAD
patients with GIB without an identified source on EGD and colonoscopy. It also
highlights the need to closely understand the pathophysiology of GIB in LVAD
patient and reassess the extrapolation of the diagnostic algorithm involving routine
CE use from the general population to the LVAD patients. Instead of offering CE to
all occult GIB cases, identification of the patients who would benefit most from a
capsule-first approach is necessary for optimum utilization of resources, reduction
of healthcare expenditure and improvement of quality-adjusted life years through
expedited discharge.
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